Released Nov 14, 2022, after the close
10-Q filed Nov 14, 2022, 45 days after period end · 0001193125-22-284583
Q3 2022 · 10-Q
Revenue—
Net Income-$10.71M-$10.71M N/M vs Q3 2021N/M vs Q2 2022
EPS Diluted-$0.26-$0.26 N/M vs Q3 2021N/M vs Q2 2022
Operating Income-$11,371,000N/M
Operating Cash Flowderived-$9,183,000N/M
Free Cash Flowderived-$9,264,000N/M
What the release said
The release
Same quarter
| Metric | Q3 2022 | Q3 2021 | Q3 2020 |
|---|---|---|---|
| Net Income | -$10.71M | -$3.90M | -$2.49M |
| EPS Diluted | -$0.26 | -$0.10 | -$5.94 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Acumen Pharmaceuticals, Inc. · CIK 1576885 · Engraved from SEC EDGAR